Sorrento Therapeutics, Inc. announced receipt of clearance from ANVISA to proceed with a Phase IIa randomized, placebo-controlled study of intravenous allogeneic adipose-derived MSC to treat post COVID-19 “long haul” pulmonary compromise.
[Sorrento Therapeutics, Inc.]
7992332
{7992332:BBBBBBBB}
apa
50
1
170844
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/